/
PARP Inhibitors This program will include a discussion of off-label treatment and investigational PARP Inhibitors This program will include a discussion of off-label treatment and investigational

PARP Inhibitors This program will include a discussion of off-label treatment and investigational - PowerPoint Presentation

conchita-marotz
conchita-marotz . @conchita-marotz
Follow
347 views
Uploaded On 2019-02-06

PARP Inhibitors This program will include a discussion of off-label treatment and investigational - PPT Presentation

PARP Inhibitors What Do We know PARP Inhibitors What Do We Know cont PARP Inhibitors What Dont We Know SOLO1 Study Rationale and Design a Primary Endpoint and Other R esults Time to Second Progression or Death ID: 750514

trial parp ovarian phase parp trial phase ovarian inhibitors maintenance cancer platinum cont olaparib nci study treatment messages sensitive

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "PARP Inhibitors This program will includ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

PARP InhibitorsSlide2
Slide3

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide4

PARP Inhibitors: What Do We know?Slide5

PARP Inhibitors: What Do We Know? (cont)Slide6

PARP Inhibitors: What Don't We Know ?Slide7

SOLO-1: Study Rationale and Design[a]Slide8

Primary Endpoint and Other R

esultsSlide9

Time to Second Progression or Death (PFS2)Slide10

SOLO-1 ConclusionsSlide11

PAOLA-1: Phase 3 Trial of Olaparib Plus Bevacizumab

vs Placebo Plus Bevacizumab as Maintenance Treatment in Advanced Ovarian CancerSlide12

VELIA: Phase 3 Trial of Veliparib With Carboplatin and Paclitaxel as Continuous MaintenanceSlide13

PRIMA: Phase 3 Trial of Niraparib vs Placebo as Maintenance Treatment in Advanced Ovarian CancerSlide14

PARP Inhibitors as Maintenance TherapySlide15

QUADRA Slide16

Updated Analysis of QUADRASlide17

ORR in Biomarker-Defined, Response-Evaluable PopulationSlide18

Strategies for the FutureSlide19

Randomized Phase 2 Trial Combining Cediranib and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerSlide20

Phase 3 NCI GY004

PFS by BRCA Status Slide21

NCI GY004 (Platinum Sensitive)Slide22

NCI GY005 (COCOS/Platinum Resistant)Slide23

ICON9: Randomized Trial of Cediranib and Olaparib Maintenance in Relapsed Platinum-Sensitive

Ovarian Cancer Slide24

MEDIOLA: Phase 2 Basket Study of Olaparib + PDL1 Antibody (Durvalumab) in

BRCA

m-Positive Relapsed Ovarian CancerSlide25

TOPACIO: Single-Arm Trial of PARP Inhibitor (Niraparib) + Anti-PDL1 (Pembrolizumab) Slide26

JAVELIN Ovarian 100 PARPSlide27

ATHENA Study DesignSlide28

Which First-Line Trials Are Enrolling Patients? Slide29

Take-Home MessagesSlide30

Take-Home Messages (cont)Slide31

Take-Home Messages (cont)Slide32